Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
16.46
+0.32 (1.98%)
At close: Jun 18, 2026, 4:00 PM EDT
16.50
+0.04 (0.24%)
After-hours: Jun 18, 2026, 7:55 PM EDT
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 128 employees as of December 31, 2025. The number of employees decreased by 2 or -1.54% compared to the previous year.
Employees
128
Change (1Y)
-2
Growth (1Y)
-1.54%
Revenue / Employee
$2,330,430
Profits / Employee
$2,329,789
Market Cap
2.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -2 | -1.54% |
| Dec 31, 2024 | 130 | -170 | -56.67% |
| Dec 31, 2023 | 300 | 0 | - |
| Dec 31, 2022 | 300 | 0 | - |
| Dec 31, 2021 | 300 | 6 | 2.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 274 |
| Immunome | 206 |
AUPH News
- 14 days ago - Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis - TheFly
- 14 days ago - LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Business Wire
- 15 days ago - Aurinia Pharmaceuticals up 4% in pre-market after insider transactions - TheFly
- 6 weeks ago - Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c - TheFly
- 6 weeks ago - Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - Business Wire
- 6 weeks ago - Aurinia Pharmaceuticals Earnings release: Q1 2026 - Filings
- 6 weeks ago - Aurinia Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 2 months ago - Aurinia Pharmaceuticals Proxy statement: Proxy filing - Filings